Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director · President and CEO | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 197,746 |
Ending reported balance
After 2026-09-11 transaction · row 24
24 source rows · reconciled sequenceRow 1 · 2026-09-09 · Sale · Disposed 131 · Balance 209,198 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 2 · 2026-09-09 · Sale · Disposed 347 · Balance 208,851 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive. Row 3 · 2026-09-09 · Sale · Disposed 522 · Balance 208,329 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive. Row 4 · 2026-09-09 · Sale · Disposed 368 · Balance 207,961 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive. Row 5 · 2026-09-09 · Sale · Disposed 512 · Balance 207,449 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive. Row 6 · 2026-09-09 · Sale · Disposed 396 · Balance 207,053 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive. Row 7 · 2026-09-09 · Sale · Disposed 644 · Balance 206,409 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive. Row 8 · 2026-09-09 · Sale · Disposed 1,040 · Balance 205,369 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive. Row 9 · 2026-09-09 · Sale · Disposed 640 · Balance 204,729 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive. Row 10 · 2026-09-09 · Sale · Disposed 520 · Balance 204,209 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive. Row 11 · 2026-09-09 · Sale · Disposed 215 · Balance 203,994 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive. Row 12 · 2026-09-09 · Sale · Disposed 505 · Balance 203,489 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive. Row 13 · 2026-09-09 · Sale · Disposed 362 · Balance 203,127 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive. Row 14 · 2026-09-09 · Sale · Disposed 160 · Balance 202,967 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive. Row 15 · 2026-09-11 · Sale · Disposed 60 · Balance 202,907 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive. Row 16 · 2026-09-11 · Sale · Disposed 106 · Balance 202,801 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive. Row 17 · 2026-09-11 · Sale · Disposed 218 · Balance 202,583 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive. Row 18 · 2026-09-11 · Sale · Disposed 160 · Balance 202,423 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive. Row 19 · 2026-09-11 · Sale · Disposed 687 · Balance 201,736 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive. Row 20 · 2026-09-11 · Sale · Disposed 368 · Balance 201,368 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive. Row 21 · 2026-09-11 · Sale · Disposed 1,202 · Balance 200,166 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive. Row 22 · 2026-09-11 · Sale · Disposed 1,539 · Balance 198,627 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive. Row 23 · 2026-09-11 · Sale · Disposed 761 · Balance 197,866 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive. Row 24 · 2026-09-11 · Sale · Disposed 120 · Balance 197,746 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive.
F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive.
F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive.
F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive.
F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive.
F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive.
F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive.
F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 120 | $546.38 | $65,565.20 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 24 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,746 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F26 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 761 | $544.83 | $414,616.16 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 23 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,866 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F25 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,539 | $544.02 | $837,252.94 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 22 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,627 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F24 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,202 | $542.60 | $652,209.05 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 21 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,166 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 368 | $541.64 | $199,324.37 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 20 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,368 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 687 | $540.59 | $371,382.38 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 19 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,736 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 160 | $537.62 | $86,018.80 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 18 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,423 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 218 | $535.94 | $116,835.68 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 17 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,583 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 106 | $534.06 | $56,610.68 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 16 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,801 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 60 | $533.09 | $31,985.48 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 15 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,907 F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 160 | $542.55 | $86,807.60 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 14 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,967 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 362 | $541.65 | $196,078.68 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 13 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,127 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 505 | $540.19 | $272,796.40 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 12 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,489 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 215 | $539.03 | $115,891.04 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 11 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,994 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 520 | $538.30 | $279,914.49 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 10 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,209 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 640 | $537.17 | $343,791.23 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 9 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,729 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,040 | $536.11 | $557,556.79 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 8 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,369 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 644 | $535.27 | $344,715.10 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 7 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,409 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 396 | $534.20 | $211,541.77 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 6 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,053 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 512 | $533.09 | $272,943.72 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 5 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,449 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 368 | $531.99 | $195,772.21 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 4 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,961 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 522 | $530.23 | $276,780.63 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 3 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,329 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 347 | $529.27 | $183,655.68 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,851 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 131 | $527.88 | $69,152.06 |
DisclosureSEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,198 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 280 | $555.05 | $155,414.00 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 11 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,329 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.00 to $555.10, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1 | $550.72 | $550.72 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 10 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,609 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 153 | $550.01 | $84,152.11 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 9 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,610 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.70 to $550.24, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 47 | $548.87 | $25,796.98 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 8 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,763 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.42 to $549.39, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 680 | $547.70 | $372,434.64 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 7 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,810 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.40 to $548.29, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 269 | $547.08 | $147,164.20 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 6 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,490 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.37 to $547.35, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 275 | $545.71 | $150,070.03 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 5 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,759 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $545.31 to $546.29, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 545 | $544.71 | $296,869.13 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 4 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,034 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.31 to $545.28, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 110 | $543.79 | $59,817.22 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 3 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,579 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.26 to $544.25, inclusive. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 140 | $542.75 | $75,984.43 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,689 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.22 to $543.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · derivative · entry 12 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. F12 · derivative.exercise_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. F12 · derivative.expiration_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 01:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer. F1 · price: On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer. Read SEC document |
| March 06, 2026 Filed Mar 6, 2026 23:49 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,663 | $431.94 | $718,316.22 |
DisclosureSEC source: 0001628280-26-015769 · wk-form4_1772840956.xml · nonDerivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,829 F2 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 18,743 | $0.00 Strike: $434.80 | $0.00 |
DisclosureSEC source: 0001628280-26-015769 · wk-form4_1772840956.xml · derivative · entry 3 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,743 Underlying: Common Stock · 18,743 shares Expires 2036-03-04 F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 14,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015769 · wk-form4_1772840956.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,492 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 26, 2026 Filed Jan 26, 2026 22:14 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,577 | $492.42 | $776,546.34 |
DisclosureSEC source: 0001628280-26-003468 · wk-form4_1769465694.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,497 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 4, 2025 22:26 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,400 | $575.34 | $1,380,816.00 |
DisclosureSEC source: 0001628280-25-055430 · wk-form4_1764887216.xml · nonDerivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,074 F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 22:26 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-055430 · wk-form4_1764887216.xml · derivative · entry 3 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. F3 · price: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. F3 · derivative.exercise_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. F3 · derivative.expiration_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. F3 · balance_after: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 22:26 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-055430 · wk-form4_1764887216.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 3, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 3. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2028, the fifth anniversary of the commencement of his employment with the Issuer. F1 · price: On December 3, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 3. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2028, the fifth anniversary of the commencement of his employment with the Issuer. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 01:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 7,279 | $445.63 | $3,243,740.77 |
DisclosureSEC source: 0001518611-25-000009 · wk-form4_1757466450.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,474 F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 21, 2025 Filed Aug 21, 2025 21:44 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,131 | $401.00 | $453,531.34 |
DisclosureSEC source: 0001518611-25-000007 · wk-form4_1755812664.xml · nonDerivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,753 F1 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $401.00 to $401.01, inclusive. Read SEC document |
| August 21, 2025 Filed Aug 21, 2025 21:44 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,485 | $400.03 | $2,594,225.03 |
DisclosureSEC source: 0001518611-25-000007 · wk-form4_1755812664.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,884 F1 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $400.00 to $400.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 22,009 | $0.00 Strike: $347.28 | $0.00 |
DisclosureSEC source: 0001628280-25-011410 · wk-form4_1741387671.xml · derivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,009 Underlying: Common Stock · 22,009 shares Expires 2035-03-05 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 13,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011410 · wk-form4_1741387671.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,369 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:36 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-009091 · wk-form4_1740778579.xml · derivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs. F2 · price: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs. F2 · derivative.exercise_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs. F2 · derivative.expiration_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs. F2 · balance_after: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:36 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-009091 · wk-form4_1740778579.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 27, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 2. Although the Issuer is irrevocably obligated to issue these shares to the Reporting Person, these shares will settle and be delivered to the Reporting Person on September 8, 2027, the fourth anniversary of the commencement of his employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.